The global biologics CDMO market size was USD 19.02 billion in 2023, calculated at USD 21.96 billion in 2024 and is expected to be worth around USD 92.37 billion by 2034. The market is slated to expand at xx% CAGR from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Biologics CDMO Market
5.1. COVID-19 Landscape: Biologics CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Biologics CDMO Market, By Type
8.1. Biologics CDMO Market, by Type, 2024-2033
8.1.1 Mammalian
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Microbial
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Biologics CDMO Market, By Molecule Type
9.1. Biologics CDMO Market, by Molecule Type, 2024-2033
9.1.1. Monoclonal Antibodies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Recombinant Proteins
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Vaccines
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Hormones
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Biologics CDMO Market, By Product Type
10.1. Biologics CDMO Market, by Product Type, 2024-2033
10.1.1. Biologics
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Biosimilars
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. By indication
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Oncology
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Auto-Immune Diseases
10.1.5.1. Market Revenue and Forecast (2021-2033)
10.1.6. Infectious Diseases
10.1.6.1. Market Revenue and Forecast (2021-2033)
10.1.7. Neurology
10.1.7.1. Market Revenue and Forecast (2021-2033)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Biologics CDMO Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.1.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2021-2033)
11.2.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.2.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2021-2033)
11.3.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.3.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.4.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.4.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.5.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.5.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Product Type (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Molecule Type (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Product Type (2021-2033)
Chapter 12. Company Profiles
12.1. 3P BIOPHARMACEUTICALS S.L.U
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AGC Biologics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Binex Co. Ltd.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Boehringer Ingelheim International GmbH
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bora Pharmaceuticals Co. Ltd
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Catalent Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Evonik Industries AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. FUJIFILM Corp.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Rentschler Biopharma SE
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Samsung Electronics Co. Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample